19 recruiting, 11 unknown, 7 completed, 2 terminated. 43 Phase 2, 9 Phase 1, 6 Phase 3.
Follow Treatment: new trials by email Literature Review of Treatment trials Research Report on Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients Melatonin - Therapy, Treatment | Phase 2 / Phase 3 | Not yet recruiting | Ain Shams University | 64 | 2026-07-21 | 2026-07-23 |
| Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 122 | 2026-03-01 | 2026-01-23 |
| Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody） - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-01 | 2026-01-23 |
| Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Daratumumab（Anti-CD38 Monoclonal Antibody）, Rituximab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-28 | 2026-02-11 |
| Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-20 | 2026-02-11 |
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML Ivosidenib, Venetoclax, Azacitidine - AML, IDH1 Mutation | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2025-10-17 | 2026-05-13 |
| Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) Daratumumab Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2025-08-01 | 2025-07-14 |
| An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia CM336 Injection - Immune Thrombocytopenia (ITP), Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-03-03 | 2025-03-13 |
| A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia nicotinamide adenine dinucleotid/nicotinamide mononucleotide - Immune Thrombocytopenia, Treatment | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-15 | 2025-08-05 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) Daratumumab Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-08-01 | 2025-08-05 |
| Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia Avatrombopag - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2024-03-01 | 2025-02-24 |
| A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia CM313 Injection, Placebo Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 45 | 2024-01-16 | 2024-12-30 |
| Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial Experimental: chemotheyapy, Active Comparator: endocrine therapy - Advanced Breast Cancer, Treatment | Phase 2 | Recruiting | Henan Cancer Hospital | 240 | 2024-01-01 | 2024-08-20 |
| Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) Anti-CD38 antibody Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2023-12-28 | 2025-11-28 |
| A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP) Obinutuzumab Injection [Gazyva] - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2023-12-01 | 2025-02-24 |
| Anti-CD38 Antibody Treating Evans Syndrome Anti-CD38 antibody Injection - Evan Syndrome, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2023-12-01 | 2025-02-21 |
| A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia Obinutuzumab Injection [Gazyva] - Immune Thrombocytopenia, Treatment | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 110 | 2023-08-28 | 2025-02-21 |
| A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia CM313 Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2023-01-22 | 2025-02-24 |
| Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration IV Methylprednisolone administration, Nasal Methylprednisolone (MT) - Multiple Sclerosis Relapsing Remitting, Treatment | Phase 2 | Enrolling by invitation | Universidad Nacional Autonoma de Mexico | 80 | 2023-01-09 | 2025-04-03 |
Showing 20 of 43. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (15) · Inflammation (2) · Adenocarcinoma of Lung (1) · Antiphospholipid Syndrome (1) · Anxiety Disorders (1) · Brain Concussion (1) · COVID-19 (1) · Cocaine-Related Disorders (1) · Corneal Dystrophies, Hereditary (1) · Crohn Disease (1) · Depression (1) · Diabetes, Gestational (1) · Evans Syndrome (1) · Eye Diseases (1) · Fatigue (1)
Immune System Diseases (19) · Pathological Conditions, Signs and Symptoms (19) · Autoimmune Diseases (18) · Pathologic Processes (18) · Hemic and Lymphatic Diseases (17) · Signs and Symptoms (17) · Blood Platelet Disorders (16) · Cytopenia (16) · Hematologic Diseases (16) · Blood Coagulation Disorders (15) · Hemorrhage (15) · Hemorrhagic Disorders (15) · Purpura (15) · Purpura, Thrombocytopenic (15) · Skin Manifestations (15)
Rituximab (4) · daratumumab (4) · Cisplatin (2) · Cyclophosphamide (2) · Dexamethasone (2) · Injections (2) · obinutuzumab (2) · zanubrutinib (2) · Aspirin (1) · Azacitidine (1) · Bortezomib (1) · Brentuximab Vedotin (1) · Capecitabine (1) · Carboplatin (1) · Control Groups (1)
Institute of Hematology & Blood Diseases Hospital, China (18) · Asociación para Evitar la Ceguera en México (2) · Centers for Disease Control and Prevention (2) · Ain Shams University (1) · Children's Cancer Group, China (1) · Chulalongkorn University (1) · Dai Huaping (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hartford Hospital (1) · Henan Cancer Hospital (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Peking Union Medical College Hospital (1) · Rush University Medical Center (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Suzhou Puhe Pharmaceutical Technology Co., LTD (1)
China (26) · United States (5) · Mexico (3) · Italy (2) · Brazil (1) · Denmark (1) · Egypt (1) · France (1) · Spain (1)
Lei Zhang, MD (12) · Barbara Soltes, MD (1) · Cai Yue (1) · David R Howell, PhD (1) · Giovanni Martinelli, Prof. (1) · Gretchen J. Diefenbach, Ph.D. (1) · Hui Wei, MD (1) · Hui Zhao, Doctor (1) · Jorge L Alio, MD, PhD (1) · Karen Flores-Guevara, MD (1) · Lei Zhang, M.D (1) · Lilli Lundby, MD (1)
PMID 21990811, PMID 22700728, PMID 28486314, PMID 29103962, PMID 30772348, PMID 32301973, PMID 32736597, PMID 33164825, PMID 33181549, PMID 33591032, PMID 33708786, PMID 36103365, PMID 37489818, PMID 37776953, PMID 38899695, PMID 39760650, PMID 40297050, PMID 40887012, PMID 40990413, PMID 41019467, PMID 41120215, PMID 41126474, PMID 41593831, PMID 41622533, PMID 41956449, PMID 42056497, PMID 42245142, PMID 42266006, PMID 42284615
2018 (1), R01HD108133 (1)